Catalyst Wire Dossier Catalyst Wire Dossier

SB2 Infliximab

infliximab · Samsung Bioepis Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SB2 Infliximab, covering 2017-10-13 to 2017-10-13. Get the full timeline:

Most recent: Clinical Trial Update: Comparison of the Performance of SB2-Infliximab With Originator Infliximab in the Measure of Serum Concentrations in Serum

See pricing